DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a research note released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Stock Up 2.5 %

Shares of DURECT stock opened at $0.77 on Friday. The company’s fifty day simple moving average is $0.83 and its two-hundred day simple moving average is $1.12. DURECT has a 12-month low of $0.70 and a 12-month high of $1.88. The firm has a market cap of $23.87 million, a PE ratio of -1.26 and a beta of 0.91.

Institutional Investors Weigh In On DURECT

A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC increased its position in DURECT by 266.0% during the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 28,486 shares during the last quarter. Geode Capital Management LLC increased its position in DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the last quarter. Finally, Richmond Brothers Inc. increased its position in DURECT by 12.2% during the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after acquiring an additional 138,920 shares during the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.